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Abstract 
Introduction: While it is well known that diabetes is common in prevalent heart failure (HF) and 
portends a poor prognosis, the role of diabetes in the development of incident HF is less well 
understood. We studied the role of diabetes in the transition from asymptomatic left ventricular 
systolic dysfunction (ALVSD) to overt HF in the prevention arm of the Studies of Left Ventricular 
Dysfunction (SOLVD-Prevention).  
Methods: We examined the development of symptomatic HF, HF hospitalization, and 
cardiovascular death, according to diabetes status at baseline in patients in SOLVD-Prevention. 
These outcomes were analyzed using cumulative incidence curves and Cox regressions models 
adjusted for age, sex and other prognostic factors including randomized treatment, HF severity and 
comorbidity.   
Results: Of the 4223 eligible participants, 647 patients (15%) had diabetes at baseline. Patients 
with diabetes were older, and had a higher average weight, systolic blood pressure and heart rate.   
During the median follow-up of 36 months, 861 (24%) of the 3576 patients without diabetes 
developed HF, compared to 214 (33%) of the 647 patients with diabetes. In unadjusted analyses, 
patients with diabetes had a higher risk of development of HF (HR=1.53 [1.32-1.78], P<0.001), HF 
hospitalization (HR=2.04 [1.65-2.52], P<0.0001), and of the composite outcome of development of 
HF or cardiovascular death (HR=1.48 [1.30-1.69], P<0.001). The effect of enalapril on outcomes 
was not modified by diabetes status. 
Conclusions: In patients with ALVSD; diabetes is associated with an increased risk of developing 
HF. Development of HF is associated with increased risk of death irrespective of diabetes status. 
Keywords: Asymptomatic left ventricular dysfunction, heart failure, diabetes 
 
 
 
Introduction 
Heart failure (HF) and type 2 diabetes mellitus are two epidemics of modern times and many 
patients suffer from both conditions. Their coexistence places these individuals at very high risk of 
adverse cardiovascular outcomes, underscoring the importance of understanding the interactions 
between the two conditions.1-6 It has long been recognized that patients with diabetes have a higher 
incidence of cardiovascular disease, including a two- to four-fold higher risk of heart failure, than 
people without diabetes.7-11 However, we do not fully understand the link between diabetes and 
development of heart failure. For example, we still do not know whether diabetes causes heart 
failure directly or whether the higher risk of heart failure simply reflects the greater frequency of 
hypertension and myocardial infarction in patients with diabetes. Of course, if diabetes does 
directly promote the development of heart failure, it should also accelerate the development of heart 
failure in patients with pre-existing sub-clinical cardiac damage. To test this hypothesis, we 
examined the progression from asymptomatic left ventricular systolic dysfunction (ALVSD) to 
overt heart failure in patients with and without diabetes in the prevention arm of the Studies of Left 
Ventricular Dysfunction (SOLVD-P). 
 
Methods 
Study population 
We used the public-use copy of the SOLVD-P database obtained from the National Heart, Lung, 
and Blood Institute which sponsored the trial. SOLVD-P was designed to study the effect of 
enalapril on the development of heart failure and on mortality in patients with ALVSD.12-14 Patients 
were eligible if they had a documented left ventricular ejection fraction (LVEF) ≤ 35%, had little or 
no limitation of exercise tolerance due to dyspnea or fatigue and were not receiving diuretics, 
 
 
 
digoxin, or vasodilators for the treatment of HF (but could receive these for other indications such 
as hypertension and atrial fibrillation). According to the SOLVD protocol, participants had to 
exhibit no symptoms or signs of overt HF during a three-week run in period. During this period, 
patients received open-label enalapril for 2 to 7 days followed by open-label placebo for 14 to 17 
days, after which they were randomly assigned 1:1 to double-blind enalapril or placebo. 
Definition of diabetes mellitus 
At baseline, investigators reported whether patients did or did not have a history of diabetes. Data 
on the duration of diabetes, glycated hemoglobin and treatments for diabetes were not collected. In 
the present analyzes we stratified patients by history of diabetes at baseline.  
Outcomes  
Patients were seen 2 and 6 weeks after randomization and at 4 months and then every 4 months 
until the end of study. The development of heart failure was a pre-specified endpoint, defined by the 
onset of symptoms and/or signs of “congestive heart failure” (shortness of breath on exertion or at 
rest, evidence of fluid retention such as peripheral edema, pulmonary congestion, jugular venous 
distension) which, in the opinion of the site investigator were sufficiently severe to warrant 
pharmacologic treatment. Hospital admission for HF and death due to heart failure were additional 
pre-specified HF endpoints (these were potentially overlapping, non-mutually exclusive events). 
In the present analyses, we examined the following outcomes: i) development of HF, ii) 
hospitalization for HF, iii) death from cardiovascular (CV) causes and iv) death from any cause 
according to diabetes status at baseline (and in the case of all-cause death, also after development of 
heart failure).  
Statistical analyses 
 
 
 
Baseline characteristics were described by use of proportions for categorical variables and means with 
standard deviations for continuous variables. Baseline differences between patients with and without 
diabetes were tested by use of χ2-test for categorical variables and ANOVA for continuous variables. 
We estimated Kaplan-Meier curves for all-cause mortality and cumulative incidence curves for all other 
outcomes with death or death from non-cardiovascular causes as a competing risk by use of the Aalen-
Johansen method.15 Log rank test and Gray’s test were used to analyze unadjusted differences, 
respectively. Event rates for each outcome of interest are presented per 1000 person years of follow-up. 
Cox proportional hazard models were used to compare the risk of patients with and without history of 
diabetes for all outcomes of interest, as well as the effect of enalapril on these outcomes according to 
diabetes status at baseline. The adjusted Cox regression models included information on age, gender, 
treatment effect, race, New York Heart Association (NYHA) class, smoking status, LVEF, systolic 
blood pressure, heart rate, creatinine level, angina at baseline and history of myocardial infarction, 
chronic obstructive pulmonary disease (COPD), stroke, atrial fibrillation and hypertension. Sex, age 
and treatment effect were tested for interactions with diabetes status in relation to all outcomes and, 
unless stated otherwise, found to be absent. Tests for interactions between atrial fibrillation and heart 
rate as well as angina at baseline and history of myocardial infarction in relation to all outcomes were 
preformed and found to be absent. The assumption of linearity was tested for age, LVEF, heart rate, 
systolic blood pressure and creatinine level.  Log (-log(survival)) curves were used to evaluate the 
proportional hazard assumption. Furthermore analyses with blood pressure, creatinine and myocardial 
infarction as time-dependent covariates were carried out. The rate of total hospitalizations for HF was 
compared by use of negative binomial regression with logarithm of the duration of follow-up as the 
offset.16   
Analyses were performed by use of Stata version 14 and R version 3.3.2.  
 
 
 
 
Results 
Baseline characteristics  
A total of 4223 patients (99.9%) had information about history of diabetes recorded. Of these, 647 
(15%) patients had a diagnosis of diabetes. Patients with diabetes were older (mean age 61 years 
compared with 58 years in patients without diabetes), more were women (15% vs 11%), they had a 
higher weight (mean 85 kg vs 82 kg), systolic blood pressure (130 mmHg vs 125 mmHg), and heart 
rate (78 bpm vs 74 bpm) and a different racial composition (77% whites and 16% blacks vs 88% 
whites and 8% blacks) (Table 1).  History of hypertension and treatment with diuretics were also 
more common among patients with diabetes, compared to those without. 
Clinical outcomes according to diabetes status 
During the median follow-up of 36 months (quartile 1-quartile 3, 26-47), 861 (24.1%) of the 3576 
patients without diabetes developed HF; among the 647 patients with diabetes, 214 (33.1%) 
developed HF (as assessed by time to first occurrence of either symptoms/signs or HF 
hospitalization – the components of this composite are show in Supplementary table 1). A median 
time to development of HF could not be calculated in patients without diabetes but the time taken 
for 25% of these patients to develop HF was1178 days, compared to 602 days in those with 
diabetes. As well as a higher risk of developing HF (Figure 1A), patients with diabetes also had a 
higher risk of HF hospitalization (Figure 1B) and of the composite endpoint of development of HF 
or cardiovascular death (Figure 1C), compared to patients without diabetes.  Patients with diabetes 
were also at greater risk of death from any cause than those without diabetes (Figure 1D). The risk 
of each of these outcomes remained elevated in patients with diabetes when examined in adjusted 
Cox regression analyses (Table 2).  
 
 
 
An incident myocardial infarction following randomization and prior to development of HF 
occurred in 5.9% of patients without diabetes compared with 5.6% among those with diabetes. In 
analyses including myocardial infarction as a time-dependent covariate, the risk of development of 
HF remained significantly higher in patients with diabetes compare to those without (adjusted 
HR=1.30 [1.11-1.52], P=0.001). Similarly, inclusion of systolic blood pressure or creatinine as 
time-dependent covariates did not weaken the association between diabetes and development of HF 
(adjusted HR=1.32 [1.12-1.54], P=0.001; HR=1.29 [1.10-1.50], P=0.002; respectively). 
The total number of admissions to hospital for HF (taking account of repeat admissions) according 
to diabetes status is shown in Supplementary table 2. The crude rate of HF hospitalizations was 110 
hospitalizations per 1000 person-years for patients with diabetes and 55 hospitalizations per 1000 
person-years among patients without diabetes. This yielded an adjusted incidence rate-ratio of 1.93 
[1.44-2.59; P<0.0001]. 
Other predictors of incident HF  
Older age, black race, NYHA class II (vs I), lower LVEF, higher heart rate and creatinine level, and 
history of COPD were all associated with development of HF (Supplementary figure 1), HF 
hospitalization and the composite endpoint of HF hospitalization and cardiovascular death (not 
shown). Diabetes remained an independent predictor of all outcomes examined, even when these 
other predictive variables were taken into account (Table 2 and Supplementary figure 1).  
Survival overall and following a HF event 
In patients who did not develop HF, the risk of death over up to 4 years of follow-up was 14% 
[12%-16%] in those without diabetes at baseline and 22% [16%-27%] in those with diabetes 
(Figure 2). In those who did develop HF, the risk of death was 29% [25%-33%] in patients without 
diabetes at baseline and 37% [29%-45%] in those with diabetes. Focusing on the period after 
 
 
 
development of HF, the risk of death was 33% [28%-37%] in patients without diabetes and 42% 
[33%-50%] in patients with diabetes (P=0.0004); the respective mortality rates were 128 (111-147) 
and 181 (143-230) per 1000 person years. The high mortality rate after development of HF was 
similar whether the first manifestation of HF was development of symptoms/signs or admission to 
hospital (Supplementary figure 2). A median time to death after development of HF could not be 
calculated, but in those without diabetes the time taken for death to occur in 25% of patients was 
862 days, compared with 478 days in patients with diabetes. 
In adjusted analyses, patients developing HF had a significantly higher risk of subsequent death 
compared with patients who did not develop HF (Table 2). However, the relative risk of death in 
patients developing HF (compared to those not developing HF) was similar in participants with and 
without diabetes.  
Effect of enalapril according to diabetes mellitus status 
The effect of enalapril on the outcomes analyzed was not modified by diabetes status as shown in 
Supplementary table 3.  Enalapril reduced the occurrence of development of HF, HF hospitalization 
and the combined endpoint of development of HF or cardiovascular death, significantly, in both 
patients with and without diabetes. Enalapril did not reduce the risk of death from cardiovascular 
causes or all-cause mortality, overall or in patients with or without diabetes. 
 
Discussion 
The SOLVD Prevention trial remains the only detailed source of information on the natural history 
of ALVSD and, in particular, on the progression of ALVSD to symptomatic heart failure. As such 
this dataset also provided a unique opportunity to investigate whether diabetes accelerates the 
progression of ALVSD to symptomatic heart failure. And that is exactly what we found – patients 
 
 
 
with diabetes were 1.5 to 2.0 times as likely to develop HF, or be hospitalized for HF. The 
occurrence of HF in patients with diabetes led to a similar relative ramping up in risk of subsequent 
death as the development of HF did in individuals without diabetes – patients who developed heart 
failure were 2 to 3 times more likely to die than those who did not develop HF, irrespective of 
baseline diabetes status. The rate of death after development of HF was higher in patients with 
diabetes than in those without. Despite their shorter life expectancy, patients with diabetes also had 
more cumulative HF hospitalizations (taking account of repeat admissions) – with double the rate of 
admissions (110 versus 55) per 1000 person years of follow-up.  
 
One of the great conundrums in this field has been the question of whether diabetes per se promotes 
the development of HF or whether the relationship between diabetes and HF is due to comorbidities 
such as myocardial infarction and hypertension.17-19 SOLVD-Prevention helps address this problem. 
Most patients in SOLVD-Prevention had a history of myocardial infarction at baseline (with a 
similar proportion in those with and without diabetes) and the occurrence of further myocardial 
infarction was systematically documented during follow-up in the trial. Few patients (<6%) who 
developed HF had a myocardial infarction reported after randomization but before the development 
of HF and accounting for these in a time-dependent co-variate analysis did not weaken the 
relationship between diabetes and development of HF. This indicates that diabetes can accelerate 
the risk of developing HF without the occurrence of further clinically recognized myocardial 
infarction. Of course patients might have experienced “silent” myocardial infarction, which may be 
more common in persons with diabetes.20 Unfortunately, “silent” myocardial infarction was not 
collected in SOLVD-Prevention although, when it has been looked for, “silent” myocardial 
infarction has been uncommon, compared with recognized infarction and is unlikely to explain the 
excess risk of heart failure. 
 
 
 
Apparently counterintuitively, we found that history of myocardial infarction was associated with 
lower likelihood of all outcomes. However, four out five patients in the study had a history of 
myocardial infarction and this finding may reflect the play of chance in the small subgroup without 
myocardial infarction. Alternatively, the alternative underlying cause of left ventricular systolic 
dysfunction in the patients without a history of myocardial infarction may have carried a 
particularly poor prognosis. 
Patients with diabetes did have a higher systolic blood pressure at baseline than those without 
diabetes but in the multivariable adjusted analysis, blood pressure or history of hypertension were 
not independent predictors of any HF outcome. Furthermore, including systolic blood pressure as a 
time-varying covariate did not attenuate the higher risk of development of HF development in 
patients with diabetes, compared to those without. Thus, among patients with symptomless left 
ventricular systolic dysfunction, higher systolic blood pressure does not seem to be a predictor of 
adverse outcomes. While this is clearly different that in patients with hypertension and 
cardiovascular disease more generally, it is also the pattern found in patients with HF and reduced 
ejection fraction where higher systolic pressure is associated with better outcomes (and low 
pressure with worse outcomes). Of course, patients with systolic dysfunction generally do not have 
substantially elevated blood pressure. 
Indeed, in the multivariable analysis, diabetes emerged as a significant predictor of developing HF. 
Other significant predictors included high heart rate, low LVEF, black race, higher creatinine, age, 
and NYHA class, along with history of COPD. This analysis points to other aspects of diabetes that 
may be critical to the development of HF. For example, renal dysfunction is a common 
consequence of diabetes and may contribute to the enhanced risk of heart failure (although baseline 
creatinine was similar in patients with and without diabetes).21, 22 Interestingly, heart rate was 
higher in patients with diabetes despite a similar prevalence of atrial fibrillation and similar use of 
 
 
 
beta-blockers and digoxin in patients with and without diabetes. It is possible that autonomic 
neuropathy might also contribute to the HF risk related to diabetes and this finding is also of 
interest in light of the benefit of heart rate-lowering therapy in patients with heart failure and 
reduced ejection fraction.23, 24  
 
We found that enalapril was as effective in reducing the development of HF in patients with 
diabetes as in those without diabetes. However, our findings also draw attention to the importance 
of understanding the cardiovascular effects of treatments for diabetes in these patients – treatments 
that might attenuate (or accentuate) the risk of developing HF. Unfortunately, such treatments were 
not recorded in SOLVD-Prevention, although when this trial was conducted there were relatively 
few choices available (largely sulfonylureas and insulin).  Sulfonylureas and insulin have both been 
associated with an increased risk of HF when compared to other treatments in observational studies, 
although there was no increase with insulin in a recent large randomized placebo-controlled trial.25-
27 The significance of this question has been highlighted in recent diabetes trials. Two with DPP-4 
inhibitors raised concerns that the agents studied might increase the risk of developing HF whereas 
two other trials with SGLT2 inhibitors have clearly shown the opposite.28-31 Unfortunately, in none 
of these trials was the heart failure phenotype described. 
 
Strengths and limitations 
The strengths of this study include the unique population of patients with ALVSD and detailed 
information on demographics, comorbidities and clinical measurements. This study also has several 
limitations. This was a retrospective analysis. We do not have data on type and duration of diabetes, 
glycated hemoglobin and medication used to treat diabetes. We do not know about possible 
undiagnosed diabetes at baseline and the development of diabetes during follow-up, allow both of 
 
 
 
these are likely to have diluted rather than exaggerated the risks reported. An immortal time bias 
was introduced in analyses of risk of death in patients developing HF (i.e. patients had to be alive 
until the development of HF). Thus, the true risk of death associated with development of HF might 
be even higher than the results we report.   
 
Conclusion 
In patients with ALVSD; diabetes mellitus is associated with an increased risk of developing HF, 
HF hospitalization and cardiovascular death.  The relative risk of death in patients developing HF 
(compared to those not developing HF) was similar high irrespective of diabetes status. This 
information might help in the development of strategies to prevent the transition from ALVSD to 
overt HF.  
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Table 1:  Baseline characteristics of patients with and without diabetes. 
    No diabetes Diabetes P-values 
Patients, n (%) 3576 (85) 647 (15)  
Age, mean ± SD 58 ± 11 61 ± 9 < 0.0001 
Male sex, n (%)        3195 (89%) 552 (85%) 0.003 
Race, n (%)     < 0.0001 
    White   3160 (88%) 494 (76%)  
    Black                301 (8%) 102 (16%)  
    Other                    112 (3%) 50 (8%)  
Enalapril treatment, n (%) 1781 (50%) 326 (50%)  
NYHA class, n (%)                0.38 
    I               2403 (67%) 417 (64%)  
    II                  1169 (33%) 229 (35%)  
    III               4 (0.1%) 1 (0.2%)  
Weight (kg), mean ± SD 81 ± 14 85 ± 15 < 0.0001 
Current Smokers, n (%)              865 (24%) 129 (20%) 0.16 
Ejection Fraction  0.28 ± 0.06 0.29 ± 0.05 0.11 
Blood pressure (mm Hg)    
   Systolic         125 ± 16 130 ± 17 < 0.0001 
   Diastolic       78 ± 10 78 ± 10 0.52 
Heart Rate (beats/min)  74 ± 12 78 ± 13 < 0.0001 
Sodium            140 ± 3 139 ± 3 < 0.0001 
Potassium           4.3 ± 0.4 4.4 ± 0.4 0.22 
Creatinine (µmol/l)          101 ± 23 102 ± 26 0.41 
Medical history    
Myocardial infarction            2873 (80%) 508 (79%) 0.31 
Atrial fibrillation 373 (10%) 75 (12%) 0.38 
COPD         180 (5%) 46 (7%) 0.03 
Stroke 200 (6%) 49 (8%) 0.05 
Hypertension         1226    (34%) 341    (53%) <   0.0001 
Angina pectoris*      1186    (33%) 245    (38%) 0.05 
Drug therapy, n (%)    
Diuretics    560    (16%) 145    (22%) <   0.0001 
Digoxin      446    (12%) 82     (13%) 0.89 
Beta-blockers   848    (24%) 167    (26%) 0.25 
Antiplatelet agents  1921    (54%) 371    (57%) 0.08 
Anticoagulant agents  444    (12%) 54     (8%) 0.003 
Antiarrhythmic drugs  569    (16%) 68     (11%) 0.0004 
Calcium-channel blockers         1216    (34%) 259    (40%) 0.02 
Abbreviations: SD - Standard deviation, COPD - Chronic obstructive pulmonary disease, * at baseline 
 
 
 
Table 2:  Event rates and hazard ratios for all outcomes according to diabetes status. 
 No. events Crude rate per 1000 py Unadjusted HR (95% CI)   P- values Adjusted HR*  (95% CI) P- values 
HF development       
Diabetes 214 157 (138-180) 1.53 (1.32-1.78) <0.0001 1.30 (1.11-1.52) 0.001 
No diabetes 861 99 (93-106) 1.00 (ref.)  1.00 (ref.)  
       
HF hospitalization       
Diabetes 114 73 (61-88) 2.04(1.65-2.52) <0.0001 1.75 (1.40-2.19) <0.0001 
No Diabetes 342 35 (32-39) 1.00 (ref.)  1.00 (ref.)  
       
HF development or CV death       
Diabetes 267 196 (174-221) 1.48 (1.30-1.69) <0.0001 1.29 (1.12-1.49) <0.0001 
No diabetes 1120 129 (122-137) 1.00 (ref.)  1.00 (ref.)  
       
CV death       
Diabetes 113 65 (54-78) 1.53 (1.25-1.89) <0.0001 1.42 (1.14-1.76) 0.001 
No diabetes 440 43 (39-47) 1.00 (ref.)  1.00 (ref.)  
       
All-cause mortality       
Diabetes 132 76 (64-90) 1.56 (1.29-1.89) <0.0001 1.43 (1.17-1.74) 0.001 
No diabetes 505 49 (45-53) 1.00 (ref.)  1.00 (ref.)  
       
All-cause mortality in relation to development of HF       
HF and diabetes 68 115 (91-146) 2.95 (2.27-3.85) <0.0001 2.47 (1.87-3.27) <0.0001 
HF and no diabetes 204 79 (69-90) 2.01 (1.68-2.40) <0.0001 1.63 (1.35-1.96) <0.0001 
No HF and diabetes 64 56 (44-71) 1.44 (1.10-1.89) 0.008 1.29 (0.98-1.71) 0.07 
No HF and no diabetes 301 39 (35-44) 1.00 (ref.)  1.00 (ref.)  
Abbreviations: HR=Hazard Ratio; PY=Person years; HF=Heart failure; CV= Cardiovascular.  
*Adjusted for age gender, treatment effect, race, NYHA class, smoking status, ejection fraction, systolic blood pressure, heart rate, creatinine levels, angina at baseline and 
history of myocardial infarction, COPD, stroke, atrial fibrillation and hypertension. 
 
 
 
Figure legends: 
Figure 1: Cumulative incidence of development of heart failure HF (A), HF hospitalization (B), 
with death as competing risk among patients with and without diabetes. Risk of developing HF, HF 
Hospitalization or cardiovascular death with non-cardiovascular death as competing risk among 
patients with and without diabetes (C). Risk of death among patients with and without diabetes (D). 
Figure 2: Risk of death according to diabetes status and development of HF.
  
 
